BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 10609795)

  • 1. Gallium scan in the evaluation of post chemotherapy mediastinal residual masses of aggressive non-Hodgkin's lymphoma.
    Ulusakarya A; Lumbroso J; Casiraghi O; Koscielny S; Vantelon JM; Girinsky T; Tardivon A; Bourhis JH; Dartevelle P; Pico JL; Munck JN
    Leuk Lymphoma; 1999 Nov; 35(5-6):579-86. PubMed ID: 10609795
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monitoring bulky mediastinal disease with gallium-67, CT-scan and magnetic resonance imaging in Hodgkin's disease and high-grade non-Hodgkin's lymphoma.
    Zinzani PL; Zompatori M; Bendandi M; Battista G; Fanti S; Barbieri E; Gherlinzoni F; Rimondi MR; Frezza G; Pisi P; Merla E; Gozzetti A; Canini R; Monetti N; Babini L; Tura S
    Leuk Lymphoma; 1996 Jun; 22(1-2):131-5. PubMed ID: 8724540
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early restaging gallium scans predict outcome in poor-prognosis patients with aggressive non-Hodgkin's lymphoma treated with high-dose CHOP chemotherapy.
    Janicek M; Kaplan W; Neuberg D; Canellos GP; Shulman LN; Shipp MA
    J Clin Oncol; 1997 Apr; 15(4):1631-7. PubMed ID: 9193363
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging.
    Jerusalem G; Beguin Y; Fassotte MF; Najjar F; Paulus P; Rigo P; Fillet G
    Blood; 1999 Jul; 94(2):429-33. PubMed ID: 10397709
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of gallium scan, computed tomography, and magnetic resonance in patients with mediastinal Hodgkin's disease.
    Devizzi L; Maffioli L; Bonfante V; Viviani S; Balzarini L; Gasparini M; Valagussa P; Bombardieri E; Santoro A; Bonadonna G
    Ann Oncol; 1997; 8 Suppl 1():53-6. PubMed ID: 9187430
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-dose therapy followed by stem cell transplantation in partial response after first-line induction therapy for aggressive non-Hodgkin's lymphoma.
    Haioun C; Lepage E; Gisselbrecht C; Coiffier B; Doyen C; Morel P; Attal M; Tilly H; Deconinck E; Gaulard P; Reyes F
    Ann Oncol; 1998; 9 Suppl 1():S5-8. PubMed ID: 9581235
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single-photon emission computed tomography gallium imaging versus computed tomography: predictive value in patients undergoing high-dose chemotherapy and autologous stem-cell transplantation for non-Hodgkin's lymphoma.
    Vose JM; Bierman PJ; Anderson JR; Harrison KA; Dalrymple GV; Byar K; Kessinger A; Armitage JO
    J Clin Oncol; 1996 Sep; 14(9):2473-9. PubMed ID: 8823325
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gallium-67 scans as an adjunct to computed tomography scans for the assessment of a residual mediastinal mass in pediatric patients with Hodgkin's disease. A Pediatric Oncology Group study.
    Weiner M; Leventhal B; Cantor A; Wimmer R; Berry DL; Cook B; Ducos R
    Cancer; 1991 Dec; 68(11):2478-80. PubMed ID: 1933785
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods?
    Spaepen K; Stroobants S; Dupont P; Van Steenweghen S; Thomas J; Vandenberghe P; Vanuytsel L; Bormans G; Balzarini J; De Wolf-Peeters C; Mortelmans L; Verhoef G
    J Clin Oncol; 2001 Jan; 19(2):414-9. PubMed ID: 11208833
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Are 18fluorodeoxyglucose positron emission tomography and magnetic resonance imaging useful in the prediction of relapse in lymphoma residual masses?
    Maisey NR; Hill ME; Webb A; Cunningham D; Flux GD; Padhani A; Ott RJ; Norman A; Bishop L
    Eur J Cancer; 2000 Jan; 36(2):200-6. PubMed ID: 10741278
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Bulky mediastinal lymphomas: role of magnetic resonance and SPECT-Ga-67 in the evaluation of residual masses].
    Canini R; Battista G; Monetti N; Pisi P; Fanti S; Zinzani PL; Zompatori M; Bendandi M; Gherlinzoni F; Corinaldesi A
    Radiol Med; 1995 Oct; 90(4):448-56. PubMed ID: 8552823
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Restaging with gallium scan identifies chemosensitive patients and predicts survival of poor-prognosis mediastinal Hodgkin's disease patients.
    Ionescu I; Brice P; Simon D; Guermazi A; Leblanc T; Rousselot P; Gossot D; Meignin V; Gisselbrecht C; Rain JD
    Med Oncol; 2000 May; 17(2):127-34. PubMed ID: 10871819
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Residual mediastinal mass in malignant lymphoma: value of magnetic resonance imaging and gallium scan.
    Brice P; Rain JD; Frija J; Miaux Y; Marolleau JP; Tredaniel J; Ferme C; Hennequin C; Gisselbrecht C
    Nouv Rev Fr Hematol (1978); 1993 Aug; 35(4):457-61. PubMed ID: 8414967
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Magnetic resonance imaging and 67Ga scan versus computed tomography in the staging and in the monitoring of mediastinal malignant lymphoma: a prospective pilot study.
    Bendini M; Zuiani C; Bazzocchi M; Dalpiaz G; Zaja F; Englaro E
    MAGMA; 1996; 4(3-4):213-24. PubMed ID: 9220410
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Residual masses on follow-up computed tomography in patients with mediastinal non-Hodgkin's lymphoma.
    Uematsu M; Kondo M; Tsutsui T; Murase T; Yorozu A; Hiramatsu H; Fujii H; Hashimoto S
    Clin Radiol; 1989 May; 40(3):244-7. PubMed ID: 2752680
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of magnetic resonance imaging and (67)gallium scintigraphy in the evaluation of posttherapeutic residual mediastinal mass in the patients with Hodgkin's lymphoma.
    Herman M; Paucek B; Raida L; Myslivecek M; Zapletalová J
    Eur J Radiol; 2007 Dec; 64(3):432-8. PubMed ID: 17478069
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term follow-up of residual mediastinal-hilar Ga-67 uptake after treatment for Hodgkin's and non-Hodgkin's lymphomas: what degree of Ga-67 uptake is significant?
    Nikpoor N; Aliabadi P; Diaz L; Mannting F
    Clin Nucl Med; 2000 Dec; 25(12):959-62. PubMed ID: 11129161
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gallium scans in the evaluation of residual masses after chemotherapy for seminoma.
    Warren GP; Einhorn LH
    J Clin Oncol; 1995 Nov; 13(11):2784-8. PubMed ID: 7595739
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Malignant lymphoma: magnetic resonance tomography findings in residual supradiaphragmatic space-occupying lesions].
    Stroszczynski C; Hosten N; Oellinger J; Spahn G; Amthauer H; Bittner RC; Hierholzer J; Ludwig WD; Felix R
    Rofo; 1999 Sep; 171(3):192-9. PubMed ID: 10520328
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Assessment of residual mediastinal tumor in patients with Hodgkin's lymphoma using computed tomography, magnetic resonance and 67Ga scintigraphy].
    Capua A; Osti MF; Scattoni Padovan F; Sarra R; Sbarbati S; Anselmo AP; Maurizi Enrici R
    Radiol Med; 1995 Dec; 90(6):797-803. PubMed ID: 8685466
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.